280 related articles for article (PubMed ID: 31665867)
21. Stuttering as the first sign of CAR-T-cell-related encephalopathy syndrome (CRES).
Gonzalez Castro LN; Dietrich J; Forst DA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1917-1918. PubMed ID: 30539279
[No Abstract] [Full Text] [Related]
22. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
Allred J; Bharucha K; Özütemiz C; He F; Janakiram M; Maakaron J; Carrier C; Grzywacz B; Bachanova V
Bone Marrow Transplant; 2021 Mar; 56(3):679-682. PubMed ID: 32764581
[No Abstract] [Full Text] [Related]
23. CAR T cell therapy for B-cell lymphomas.
Chavez JC; Locke FL
Best Pract Res Clin Haematol; 2018 Jun; 31(2):135-146. PubMed ID: 29909914
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
25. CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong EA; Levine BL; Grupp SA; Davis MM; Siegel DL; Maude SL; Gladney WL; Frey NV; Porter DL; Hwang WT; Chong ER; June CH; Schuster SJ
Blood; 2019 Nov; 134(21):1873-1875. PubMed ID: 31554634
[No Abstract] [Full Text] [Related]
26. Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Snyder S; Chung KC; Jun MP; Gitlin M
Adv Ther; 2021 Sep; 38(9):4659-4674. PubMed ID: 34302277
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma.
Houot R; Armand P; Jacobson CA
Eur J Cancer; 2020 May; 131():51-52. PubMed ID: 32283478
[No Abstract] [Full Text] [Related]
28. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
Havard R; Stephens DM
Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
[TBL] [Abstract][Full Text] [Related]
29. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
30. Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Parikh RR; Milgrom SA; Campbell BA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1152-1158. PubMed ID: 38492961
[No Abstract] [Full Text] [Related]
31. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
32. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Figura NB; Robinson TJ; Sim AJ; Wang X; Cao B; Chavez JC; Shah BD; Khimani F; Lazaryan A; Davila M; Bachmeier C; Nishihori T; Liu HD; Kim S; Locke FL; Jain MD
Int J Radiat Oncol Biol Phys; 2021 Dec; 111(5):1145-1154. PubMed ID: 34242714
[TBL] [Abstract][Full Text] [Related]
33. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.
Cliff ERS; Merryman RW; Armand P; Jacobson CA
Nat Med; 2022 Dec; 28(12):2458-2459. PubMed ID: 36348063
[No Abstract] [Full Text] [Related]
34. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD; Gordon LI; Abramson JS; Advani RH; Bartlett NL; Caimi PF; Chang JE; Chavez JC; Christian B; Fayad LE; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Kaminski MS; Kelsey CR; Khan N; Krivacic S; LaCasce AS; Mehta A; Nademanee A; Rabinovitch R; Reddy N; Reid E; Roberts KB; Smith SD; Snyder ED; Swinnen LJ; Vose JM; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2019 Jun; 17(6):650-661. PubMed ID: 31200358
[TBL] [Abstract][Full Text] [Related]
35. Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022;139(18):2737-2746.
Blood; 2023 Feb; 141(6):683. PubMed ID: 36757722
[No Abstract] [Full Text] [Related]
36. Medical crowdfunding to access CAR T-cell therapy.
Ho LD; Oso SO; Levine AD
Lancet Oncol; 2019 Aug; 20(8):1062-1064. PubMed ID: 31486373
[No Abstract] [Full Text] [Related]
37. Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Mao Y; Huang L; Ruan H; Guo Y; Ni S; Ling Y
Support Care Cancer; 2023 Apr; 31(5):303. PubMed ID: 37099077
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
[TBL] [Abstract][Full Text] [Related]
39. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
40. Comparing axi-cel and standard of care in relapsed/refractory large B-cell lymphoma: a review of recent data on Q-TWiST, survival insights, and chimeric antigen receptor T-cell therapy considerations.
El-Cheikh J; Saleh M; Marjanovic Z; Alsuliman T
Ann Palliat Med; 2024 Jan; 13(1):190-193. PubMed ID: 37993403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
